Valuation: NEOVACS

Market Cap 4.09K 4.67K 3.79K 3.49K 6.58K 449K 6.66K 45.22K 17.69K 220K 17.51K 17.14K 760K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -229K -186K -171K -323K -22.08M -327K -2.22M -870K -10.82M -861K -842K -37.37M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
3 years 16,000
Extreme 16000
1,000,000
5 years 16,000
Extreme 16000
1,000,000
10 years 16,000
Extreme 16000
1,000,000
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 30/09/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 27/05/2003
Director/Board Member - 30/04/2020
Chairman - -
Change 5-day change 1-year change 3-year change Capi.($)
-20.00%-.--% - - 142K
-3.62%-6.74%-2.31%+11.68% 48.5B
+1.61%-0.91%+377.07%+584.68% 38.97B
+2.61%+3.96%+9.16%+61.36% 35.43B
-1.12%-2.99%+26.84%-11.67% 33.65B
-0.58%-0.69%-0.56%+30.30% 26.58B
+1.37%-3.90% - - 16.82B
+0.71%-0.84%+72.13%+116.76% 15.18B
+0.72%+1.24%+10.73%+14.64% 13.89B
+0.26%-0.80%+19.33%-32.25% 12.76B
Average -1.80%-0.93%+64.05%+96.94% 26.87B
Weighted average by Cap. -0.11%-1.00%+76.84%+122.25%

Financials

2023 2024
Net sales 533K 609K 494K 455K 858K 58.61M 868K 5.9M 2.31M 28.72M 2.28M 2.24M 99.18M 434K 495K 402K 370K 698K 47.68M 706K 4.8M 1.88M 23.37M 1.86M 1.82M 80.68M
Net income -8.74M -9.98M -8.1M -7.46M -14.06M -961M -14.23M -96.69M -37.84M -471M -37.45M -36.64M -1.63B -32.91M -37.55M -30.5M -28.07M -52.93M -3.62B -53.57M -364M -142M -1.77B -141M -138M -6.12B
Net Debt -237K -270K -219K -202K -380K -25.99M -385K -2.62M -1.02M -12.74M -1.01M -991K -43.97M -205K -234K -190K -175K -330K -22.53M -334K -2.27M -887K -11.04M -878K -859K -38.13M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
16